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DOUBLE-BLIND STUDY OF THE REVERSAL OF
MIDAZOLAM-SUPPLEMENTED GENERAL ANAESTHESIA
WITHRO15-1788f
E. ALON, L. BAITELLA AND G. HOSSLI
Several studies in animals have shown that the
specific benzodiazepine antagonist Ro 15-1788 is
highly effective in antagonizing the central effects
of benzodiazepines by competitive inhibition
(Mohler and Richards, 1983; Little and Bichard,
1984). Studies in healthy volunteers, and in
patients, have shown that Ro 15-1788 can reverse
benzodiazepine-induced sedation without pro-
ducing toxic side effects (Darragh et al., 1982;
Lauven et al., 1985). The purpose of this study
was to evaluate the actions of Ro 15-1788 used to
reverse midazolam given as part of a general
anaesthetic technique for laparoscopy.
PATIENTS AND METHODS
Sixty women (ASA grades I and II) who were to
undergo laparoscopy gave informed consent for
inclusion in the study. Exclusion criteria were
pregnancy, drug hypersensitivity or addiction to
benzodiazepines. All patients were premedicated
with midazolam 7.5 mg by mouth and anaesthesia
was induced with midazolam 0.2 mg kg"1. Suxa-
methonium was given to facilitate tracheal intu-
bation. Anaesthesia was maintained with 50%
nitrous oxide in oxygen and 0.6-1.5% enflurane.
Supplements of midazolam 0.1 mg kg"1 were
given when needed. Neuromuscular blockade was
obtained with atracurium. At the end of surgery
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SUMMARY
The actions and side effects of the benzodiaze-
pine antagonist Ro 15-1788 were evaluated in a
randomized double-blind clinical study in which
midazolam was used as an anaesthetic agent.
Sixty women who underwent laparoscopy were
treated with Ro 15-1788 or with placebo after
the surgical procedure. Ro 15-1788 reversed the
hypnotic effect of midazolam within a few
minutes. The patients were alert, co-operative,
oriented and had good recall of events after
awakening. The effects were statistically better
than placebo for up to 30 min after administra-
tion. Arterial pressure and heart rate remained
stable and there were no significant side effects.
The availability of Ro 15-1788 allows effective
reversal of midazolam when this is used during
general anaesthesia.
the enflurane and nitrous oxide were discontinued
and neuromuscular blockade antagonized with
neostigmine. After extubation of the trachea, 2 ml
of a solution containing Ro 15-1788 0.2 mg or
placebo was injected. Increments of 1 ml were
given every 30 s until the patient was awake or a
total of 10 ml had been given. The study was
double-blind and patient allocation was random.
The patients were assessed before, and 5, 15,
30, 60 and 120 min after injection. The degree of
sedation was graded on a scale of 0-3 (0 = sleepy
not arousable; 1 = sleepy but arousable;
2 = drowsy and 3 = alert). Co-operation and
comprehension, evaluated by orders to raise the
head and to shake hands, were graded on a scale
of 0-2 (0 = no execution of the order;
1 = imitation only and 2 = execution of the
order). Orientation was graded from 0 to 2
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according to the patient's awareness of the day of
the week and where she was (0 = disorientation;
1 = orientation in time or in space and
2 = orientation in time and in space). Amnesia
(0 = none; 1 = slight; 2 = moderate and
3 = marked amnesia) was tested by showing
the patients pictures and evaluating subsequent
recall.
Arterial pressure, heart rate, side effects (graded
as mild, moderate and severe) and the need for
analgesics during the first 24 h after surgery were
also monitored. Subjective assessment of awaking
was evaluated 1, 2 and 4 h after injection and
graded on a 4-point scale (0 = poor; 1 = satis-
factory; 2 = good and 3 = excellent awakening).
Results were analysed using the two sided
Mann-Whitney U test for evaluating the efficacy
of Ro 15-1788 and for the haemodynamic
variables. Fischer's exact test was used to compare
the side effects. Values were considered significant
when P < 0.05.
RESULTS
Table I shows that the two groups of patients were
comparable in respect of age, weight and height as
well as duration of operation and of anaesthesia.
The dose of midazolam (mean±SD) used was
17.3 mg±6 in the test group and 16.6 mg±4.6 in
the placebo group. In both groups midazolam
0.27 mg kg~l was required. Figure 1 shows the
results in the two groups. Before the injection of
Ro 15-1788 there was no difference between the
groups: all patients were asleep, unrousable and
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FIG. 1. Patients' clinical condition after injection of trial drug or placebo (mean ± confidence intervals).
•Statijtically significant (P < 0.05). • • = Ro 15-1788; • - - - • = placebo.
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TABLE I. Details of patients included in the study, duration of
surgery and duration of anaesthesia in both groups of patients
(mean±SD)
Age(yr)
Weight (kg)
Height (cm)
Duration of surgery (min)
Duration of
anaesthesia (min)
Ro 15-1788
30.7 ±6.3
62.0 ±22.5
157.8±16.8
38.4±15.7
56.7±16.9
Placebo
35.9±6.8
60.2 + 9.5
164.2±6.7
43.0±15.1
58.3±14.6
TABLE 11. Side effects after injection of trial drugs in both groups
of patients. * Statistically significant difference (P < 0.05)
Side effects Ro 15-1788 Placebo
Nausea*
Vomiting
Tremor
Involuntary movements
Headache
11
5
6
5
1
3
4
4
4
3
unco-operative (graded 0). Orientation and am-
nesia were therefore graded 0. Five minutes after
the injection the differences between the groups
were statistically significant and at 15 and 30 min
the patients given Ro 15-1788 were fully awake,
co-operative, oriented in time and space and had
no amnesia. In contrast, patients who received
placebo remained sleepy, unco-operative and
disoriented, with slight to moderate amnesia. By
2 h, performance was similar in both groups: all
patients were awake. The amount of Ro 15-1788
required varied between 0.3 and 1 mg (mean dose
0.6 mg;SD 0.27).
Systolic and diastolic arterial pressures and
heart rate remained stable and did not differ
significantly between the two groups. Mild to
moderate pain at the site of i.v. injection was
reported by eight patients who received Ro
15-1788 and five in the placebo group, a difference
which was not statistically significant. No local
irritation and no signs of thrombophlebitis were
observed in any of the patients. Side effects are
shown in table II. The difference between the
groups was statistically significant only for nausea,
which was graded as only mild or moderate. The
postoperative requirement for analgesics was the
same in both groups.
All patients reported good to excellent subjec-
tive impressions of awakening.
DISCUSSION
This study was undertaken to evaluate Ro
15-1788 and its side effects when given after
midazolam-supplemented general anaesthesia.
Previously, Lauven and colleagues (1985) admini-
stered Ro 15-1788 10 mg i.v. in the presence of a
stable concentration of midazolam and demon-
strated its prompt effect in an open study.
Doenicke and colleagues (1984) showed that Ro
15-1788 0.1 mg kg"1 could antagonize an anaes-
thetic dose of fiunitrazepam. This study demon-
strated that Ro 15-1788 0.01 mg kg"1 could
antagonize an anaesthetic dose of midazolam.
The effectiveness of Ro 15-1788 was demon-
strated by comparing with placebo its effect on
alertness, orientation, comprehension of and co-
operation with commands, and recall at the end
of anaesthesia. The results indicated that recovery
was much faster after the administration of Ro
15-1788. No rebound effects were encountered,
probably because of the relatively small amount of
benzodiazepine administered. Reports on patients
comatose as a result of benzodiazepine intoxication
have shown that repeated doses of Ro 15-1788
may be required (Geller, Niv and Silbiger, 1985).
In an animal experiment Glisson and Falinski
(1984) showed that Ro 15-1788 reversed the effect
of midazolam on catecholamines without ad-
versely affecting haemodynamic stability and, in
the present study, haemodynamic stability was
maintained. Local tolerance of the drug was good
and no potentially serious side effect occurred.
There was more nausea in the Ro 15-1788 group
and there were a few patients in both groups who
reported a mild or moderate degree of tremor and
involuntary movement. These results suggest
that Ro 15-1788 may be a useful addition to the
armamentarium of any anaesthetist using
benzodiazepines.
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